New use of harpagide
Harbaginoside improves metabolic homeostasis through multiple mechanisms, solving the problem that existing synthetic drugs cannot sustainably improve metabolic homeostasis. It enables new drug applications such as lowering blood sugar, lowering blood lipids, anti-inflammation, and regulating gut microbiota, thus improving diseases related to metabolic homeostasis imbalance.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- XIAMEN MEDICAL COLLEGE
- Filing Date
- 2026-06-15
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies have limitations in the prevention and control of diseases related to metabolic homeostasis imbalance, with disease treatment as the core focus. Furthermore, synthetic drugs are difficult to achieve sustained improvement in metabolic homeostasis, and the medicinal value of plant-derived natural chemical components such as harbazoside is not fully utilized.
Harbaginoside and its derivatives, stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, amorphous substances, isotopes, polymorphs, or solvates are used to prepare drugs that lower blood sugar, lower blood lipids, have anti-inflammatory effects, and regulate gut microbiota. Harbaginoside inhibits the expression of hepatic gluconeogenesis-related genes by activating the AKT/FOXO1 signaling pathway, regulates hepatic macrophage polarization, and improves metabolic homeostasis.
Harbagulet effectively lowers postprandial and fasting blood glucose, inhibits amylase activity, improves glucose tolerance, lowers blood lipids, regulates gut microbiota, improves liver transcriptomics, activates the AKT/FOXO1 signaling pathway, inhibits the expression of hepatic gluconeogenesis-related genes, regulates hepatic macrophage polarization, reduces inflammation, and improves metabolic homeostasis.
Smart Images
Figure CN122398838A_ABST